
Leading Onychomycosis Treatment Drug Class Markets Databank
Description
Leading Onychomycosis Treatment Drug Class Markets Databank
The Onychomycosis Treatment market was valued at $4,200.0 Million in 2020, and is projected to reach $11,101.3 Million by 2029 growing at a CAGR of 11.47% from 2021 to 2029. Allylamine segment is expected to be the highest contributor to this market, with $1,432.5 Million in 2020, and is anticipated to reach $3,805.1 Million by 2029, registering a CAGR of 11.53%. Griseofulvin segment is anticipated to reach $1,401.5 Million by 2029 with the highest CAGR of 11.68%. Allylamine and Azole segments collectively expected to account for about 63.4% share of the Onychomycosis Treatment market in 2020, with the former constituting around 34.1% share. Griseofulvin and Allylamine segments are expected to witness significant growth rates at a CAGR of 11.68% and 11.53% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 46.5% in the overall Onychomycosis Treatment market in 2020, and is anticipated to reach 46.9% by 2029.
The Onychomycosis Treatment market was valued at $4,200.0 Million in 2020, and is projected to reach $11,101.3 Million by 2029 growing at a CAGR of 11.47% from 2021 to 2029. Allylamine segment is expected to be the highest contributor to this market, with $1,432.5 Million in 2020, and is anticipated to reach $3,805.1 Million by 2029, registering a CAGR of 11.53%. Griseofulvin segment is anticipated to reach $1,401.5 Million by 2029 with the highest CAGR of 11.68%. Allylamine and Azole segments collectively expected to account for about 63.4% share of the Onychomycosis Treatment market in 2020, with the former constituting around 34.1% share. Griseofulvin and Allylamine segments are expected to witness significant growth rates at a CAGR of 11.68% and 11.53% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 46.5% in the overall Onychomycosis Treatment market in 2020, and is anticipated to reach 46.9% by 2029.
Table of Contents
85 Pages
- 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, BY DRUG CLASS
- 1.1. OVERVIEW
- 1.2. ALLYLAMINE
- 1.2.1 ALLYLAMINE MARKET, BY REGION
- 1.2.1.1 North America Allylamine Market, By Country
- 1.2.1.2 Europe Allylamine Market, By Country
- 1.2.1.3 Asia-Pacific Allylamine Market, By Country
- 1.2.1.4 Rest of World Allylamine Market, By Country
- 1.3. AZOLE
- 1.3.1 AZOLE MARKET, BY REGION
- 1.3.1.1 North America Azole Market, By Country
- 1.3.1.2 Europe Azole Market, By Country
- 1.3.1.3 Asia-Pacific Azole Market, By Country
- 1.3.1.4 Rest of World Azole Market, By Country
- 1.4. GRISEOFULVIN
- 1.4.1 GRISEOFULVIN MARKET, BY REGION
- 1.4.1.1 North America Griseofulvin Market, By Country
- 1.4.1.2 Europe Griseofulvin Market, By Country
- 1.4.1.3 Asia-Pacific Griseofulvin Market, By Country
- 1.4.1.4 Rest of World Griseofulvin Market, By Country
- 1.5. OTHER DRUG CLASS
- 1.5.1 OTHER DRUG CLASS MARKET, BY REGION
- 1.5.1.1 North America Other Drug Class Market, By Country
- 1.5.1.2 Europe Other Drug Class Market, By Country
- 1.5.1.3 Asia-Pacific Other Drug Class Market, By Country
- 1.5.1.4 Rest of World Other Drug Class Market, By Country
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.